Prognostic impact of circulating tumor cells in patients with ampullary cancer

Sun, Bo; Liang, Han; Wang, Shengnan; Xiang, Jianbin; Liu, Xingdang

doi:10.1002/jcp.26353

Cited by 11 publications

(7 citation statements)

References 34 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most reliable prognostic markers for ampullary cancer may be lymph node involvement, grading, serum CEA level, and cancer staging [ 14 , 15 ]. This study demonstrated that not only these traditional factors but also the biomarker of cfDNA level, had prognostic value for patients with ampullary cancer.…”

Section: Discussionmentioning

confidence: 99%

Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer

Shyr

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

Circulating cell-free DNA (cfDNA) in ampullary cancer patients was measured to clarify the correlation between cfDNA and clinicopathological factors and the impact of cfDNA on survival outcomes. Patients with ampullary cancer undergoing pancreaticoduodenectomy were included. Correlations between cfDNA and clinicopathological and prognostic factors were determined. The cfDNA levels in patients ranged from 1282 to 21,674 copies/mL, with a median of 6687 copies/mL. The cfDNA level was significantly higher in patients with lymph node involvement, lymphovascular invasion, abnormal serum carcinoembryonic antigen (CEA) level, and stage II and III cancer. Poor prognostic factors for ampullary cancer included high cfDNA > 6687 copies/mL, lymph node involvement, abnormal serum CEA > 5 ng/mL, and advanced stage II and III cancer. The 1- and 5-year survival rates were 92.0% and 66.5%, respectively, for patients with low cfDNA < 6687 copies/mL and 84.0% and 49.9%, respectively, for patients with high cfDNA > 6687 copies/mL (p < 0.001). After multivariate analysis, only the cfDNA level and stage were independent prognostic factors of ampullary cancer. Thus, the cfDNA level could act as a surrogate marker of both disease extent and biological aggressiveness of ampullary cancer. Moreover, cfDNA plays a significant role in the prognosis of resectable ampullary cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer

Shyr

Chen

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Nowadays, the combination of negative enrichment and imFISH, a strategy involving both epithelial and mesenchymal tumor cells detectable, showed great potential for CTC detection as it yielded a sensitivity of 76.2%, 69.4% and 75.8% for ovarian, ampullary and pancreatic cancer, respectively [17][18][19]. Based on the combination of negative enrichment and imFISH, two studies from Peking Union Medical College revealed that CTCs were detected in 84.25% or 87% of advanced NSCLC, which provided valuable prognostic information for NSCLC [12,20].…”

Section: Discussionmentioning

confidence: 99%

Circulating Tumor Cells as a Biomarker for Precise Management of Lung Cancer

Yang

2021

Preprint

View full text Add to dashboard Cite

Background: Circulating tumor cells (CTCs) with potential utility in cancer treatment provide a less invasive way to illustrate the pathogenesis of tumor. In this study, we evaluated the efficiency of CTCs in early diagnosis and/or precisely indication of lung cancer (LC) patients responding to chemotherapy.Methods: Fifty-six patients newly diagnosed with LC were included in this study, while 42 patients with nonmalignant pulmonary disease were included as positive control group and 27 healthy individuals as control. CTCs were measured at baseline in all eligible subjects and after two cycles of chemotherapy in 25 advanced LC patients, with a strategy of negative enrichment combined with immunostaining-fluorescence in situ hybridization (imFISH). The receiver operating characteristic (ROC) curve was plotted to determine the sensitivity and specificity of the CTC for the LC diagnosis. Kaplan-Meier curve and two-sided log-rank test were used for univariate survival analysis.Results: The number of CTCs was significantly increased in LC patients, compared with positive control and healthy controls. The sensitivity and specificity were 87.5% and 95.7%, with a cutoff value of 2 cells/3.2ml (AUC=0.975, 95%CI, 0.953-0.998, p=0.001). Moreover, the sensitivity of CTCs was much higher than individual or the combination of serum tumor markers (NSE/CYFRA21-1/CEA), especially in the early diagnosis of LC. Twenty-five advanced LC patients were subsequently followed up for an average of 18.2 months (6-36 months). Decline of CTC count after two cycles of chemotherapy was highly predictive for progression free survival (PFS) (13.5 vs. 8.5 months; p=0.025) and overall survival (OS) (27.6 vs. 16.8 months; p=0.009). Among the patients classified as stable disease (SD) based on post-treatment CT scan after two cycles of chemotherapy, there was significant elevation in the PFS (14.0 vs. 8.7 months; p=0.033) and OS (25.8 vs. 15.9 months; p=0.018) in those with decreased CTC number compared with those presenting stable or elevated CTCs number.Conclusions: CTCs may act as precise biomarker for early detection and therapy monitoring of LC. It may serve as good compensation for imaging.

show abstract

“…Combining negative enrichment and imFISH, a strategy that is independent of epithelial marker expression and tumour size, has shown great potential for CTC detection, yielding diagnostic sensitivities of 84, 76.2 and 69.4% for detecting CTCs in lung, ovarian and ampullary cancer, respectively (22)(23)(24). In the present study, the Cyttel method (combining probes for CEP7 and CEP8 with an anti-CD45 antibody) was designed to detect CTCs in patients with CRC and in healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Significant diagnostic value of circulating tumour cells in colorectal cancer

Hai-jiao

Zhu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Circulating tumour cells (CTCs) have potential utility in various clinical applications for cancer management. The present study focused on evaluating the diagnostic role of CTCs in colorectal cancer (CRC). A total of 89 blood samples from 59 patients diagnosed with CRC and 30 healthy individuals were collected for CTC detection. The Cyttel method is an improved CTC detection strategy, which combines negative enrichment with immunofluorescence and fluorescence in situ hybridization. This method effectively detected a significant increase in total CTCs in patients with CRC (49/59) compared with those in healthy controls (3/30). A cut-off value of 2 CTCs/3.2 ml blood yielded a sensitivity of 83.05% and a specificity of 100%. Additionally, three traditional serum tumour markers, namely carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9) and CA72-4, were examined by immunoassays. The diagnostic sensitivity of CTCs was much higher than that of CEA, CA19-9 and CA72-4 alone or in combination, particularly in patients with early stage CRC. The combined sensitivity of CTCs and CEA reached 91.53%, which was only slightly lower than the sensitivity of all four markers combined (CTCs + CEA + CA19-9 + CA72-4). CTCs with aneuploidy of chromosome 7 or 8 were carefully distinguished, and the associations among different types of CTCs, clinicopathological characteristics and overall survival were statistically analysed. Total CTCs were revealed to be significantly associated with tumour differentiation and nerve invasion. CTCs were more likely to be detected in poorly differentiated CRC tumours than in well-and moderately-differentiated tumours (P=0.026). Furthermore, to the best of our knowledge, the present study was the first to report that CTCs with multiploidy of chromosome 7 were significantly associated with TNM stage. These CTCs exhibited a high chance of being identified in the peripheral blood of patients with late-stage CRC (stage III-IV; P=0.031). The present study suggests that the combination of CTCs and CEA may serve as an effective potential diagnostic and prognostic indicator in patients with CRC. Detection of CTCs with aneuploidy may have increased specificity in predicting highly malignant and invasive tumours in CRC management.

show abstract

Prognostic impact of circulating tumor cells in patients with ampullary cancer

Cited by 11 publications

References 34 publications

Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer

Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer

Circulating Tumor Cells as a Biomarker for Precise Management of Lung Cancer

Significant diagnostic value of circulating tumour cells in colorectal cancer

Contact Info

Product

Resources

About